Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326060 | 0.78 | ABL1 (0.33) | CA2 | |
| SCHEMBL6269289 | 0.73 | CHRNA7 (0.31) | — | |
| SCHEMBL6318067 | 0.70 | CA2 (0.34) | CA2 | |
| SCHEMBL6325628 | 0.69 | NPC1 (0.31) | CA2 | |
| SCHEMBL6319742 | 0.63 | CHRNA7 (0.31) | — | |
| SCHEMBL6320139 | 0.61 | ALPL (0.40) | — | |
| SCHEMBL6317568 | 0.61 | CA2 (0.36) | CA2 | |
| SCHEMBL6318976 | 0.61 | CA2 (0.32) | CA2 | |
| SCHEMBL6320298 | 0.60 | HSD17B10 (0.33) | CA2 | |
| SCHEMBL6317887 | 0.60 | CA2 (0.31) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | CA2 2047/4885HTR1A 1141/4885 |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | CA2 3171/4885HTR1A 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.